1206102-06-8

Basic information

• Product Name: 3-Benzyloxy-1-(2,3-dihydroxy-propyl)-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid
• Synonyms: 3-Benzyloxy-1-(2,3-dihydroxy-propyl)-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid;1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic acid
• CAS NO: 1206102-06-8
• Molecular Formula: C₁₆H₁₇NO₆
• Molecular Weight: 319.30928
• Mol File: 1206102-06-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Solubility: DCM, DMSO, Methanol
• CAS DataBase Reference: 3-Benzyloxy-1-(2,3-dihydroxy-propyl)-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Benzyloxy-1-(2,3-dihydroxy-propyl)-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid(1206102-06-8)
• EPA Substance Registry System: 3-Benzyloxy-1-(2,3-dihydroxy-propyl)-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid(1206102-06-8)

Safety Data

• Hazardous Substances Data: 1206102-06-8(Hazardous Substances Data)

Usage

Description

3-Benzyloxy-1-(2,3-dihydroxy-propyl)-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid is a complex organic compound characterized by its unique molecular structure. It is an intermediate in the synthesis of various pharmaceutical compounds, particularly those used in the treatment of viral infections.

Uses

Used in Pharmaceutical Industry:
3-Benzyloxy-1-(2,3-dihydroxy-propyl)-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid is used as an intermediate in the synthesis of Dolutegravir (D528800), a second-generation HIV-1 integrase strand transfer inhibitor. Its role in the production of this medication is crucial, as it helps in the development of a more effective treatment for HIV-1 infections.
Application Reason:
The compound's unique structure allows it to be a key component in the synthesis of Dolutegravir, which is an important drug in the fight against HIV-1. By serving as an intermediate, it contributes to the development of a more potent and targeted treatment option for patients suffering from this viral infection.

Upstream product

• 616-30-8 3-Amino-1,2-propanediol 
• 119736-16-2 3-(benzyloxy)-1-((tert-butoxycarbonyl)amino)-4-oxo-1,4-dihydropyridine-2-carboxylic acid ethyl ester 
• 118-71-8 Maltol 
• 100-39-0 benzyl bromide 
• 61049-69-2 3-O-benzylmaltol 
• 1206102-04-6 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one 
• 1206102-05-7 2-[(E)-2-phenylethenyl]-3-[(phenylmethyl)oxy]-4H-pyran-4-one 
• 1229006-11-4 C₂₀H₁₆O₃ 
• 500371-01-7 3-(benzyloxy)-4-oxo-4H-pyran-2-carbaldehyde 
• 100-44-7 benzyl chloride 

Downstream Products

• 1206102-07-9 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic acid methyl ester 
• 1206102-08-0 methyl 1-(2,2-dihydroxyethyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate 

Relevant articles and documents

Practical Synthetic Method for the Preparation of Pyrone Diesters: An Efficient Synthetic Route for the Synthesis of Dolutegravir Sodium

A highly efficient and practical synthetic method for the preparation of pyrone diesters was established. The pyrone diester 3c can be prepared from readily available starting materials on a multihundred gram scale. The pyrone diester 3c can easily be converted to dolutegravir sodium (1). The synthetic route demonstrated herein provides an efficient and atom-economical synthetic method for preparing this potent anti-HIV agent.

Improved method for synthesizing dolutegravir

The invention relates to an improved method for synthesizing dolutegravir and belongs to the field of medicinal chemistry. The method takes maltol (compound 1) as a raw material, and a target is synthesized by the following route. The process raw material is cheap and easy to obtain, a reaction solvent can be recycled, the post-treatment operation is simple, the yield and the purity are high, especially the carbamoylation and debenzylation reaction are carried out in one step, the synthesis route is simplified, the cost is reduced, and the large-scale industrial production is facilitated.

TETRACYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS

The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein n, X, Y, Z, R1, R2, and R3 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.